Understanding Macular telangiectasia
Type 2 MacTel usually affects both eyes but can be uneven. It is now understood as a neurodegenerative retinal disorder with associated vascular changes, rather than simply a collection of leaking vessels. Reading difficulty may be greater than a single-letter acuity result suggests. [1] [5] [6]
Treatment information needs a date. In March 2025 the US FDA approved ENCELTO, a surgically placed cell-based implant for adults with idiopathic type 2 MacTel. Older respected pages saying there is no approved treatment are therefore outdated for that US indication; approval does not mean reversal of existing damage or identical access worldwide. [3] [4] [7]
One condition. Different experiences.
Explore different selected symptom features, then read how they may vary. These examples are not stages or a clinical test.
Original VisualSim schematic illustrations, informed by the cited clinical descriptions. These are not study figures, patient recordings or validated severity levels.
Words have gaps
Small areas of reduced sensitivity near fixation may interrupt words and slow reading. Enlarging text or using audio can help even if the clinic chart still records relatively good central acuity. [1] [5]
Distortion and reduced detail
Fine lines can bend or a small area can fade. The affected location and degree differ between eyes, so an illustrative central patch should not be treated as a universal map of MacTel. [1] [2]
Uneven or slowly changing vision
Many changes are gradual, while a complication can produce a more abrupt decline. Preserved peripheral vision is different from having no visual disability; central tasks can remain demanding. [2] [6]
Underlying degeneration and a treatable complication
Original teaching schematic; not a retinal photograph, severity scale or universal disease course. [1] [5] [8]
Original VisualSim teaching diagram · © VisualSim. Clinical basis in linked sources; not a published study figure. Image provenance.- Type 2 pattern
Photoreceptor and support-cell changes occur with altered small retinal vessels.
- Imaging
Cavities and photoreceptor-layer loss need interpretation beyond leakage alone.
- Complication check
New abnormal vessels create a separate treatment question.
What is happening—and what remains uncertain
In type 2, changes in retinal support cells and photoreceptors occur alongside altered capillaries around the fovea. OCT may show photoreceptor-layer disruption and cavities without the retinal thickening typical of ordinary edema. Dye leakage therefore does not automatically mean the same problem or treatment as diabetic swelling. [1] [5]
Some eyes develop secondary macular neovascularization: abnormal new vessels that can bleed or leak. This complication is distinct from the underlying non-neovascular degeneration. Clinical imaging is used to decide which process is active, rather than treating every angiographic leak alike. [2] [5] [8]
What can look similar?
Type 1 and type 2 are different
Type 1 is more often a unilateral vascular disorder with edema, while type 2 is usually bilateral and includes neurodegeneration. The US implant indication and the phase 3 results concern adult idiopathic type 2, not every condition called telangiectasia. [1] [3]
Similar-looking symptoms can have different causes. A matching picture cannot establish a diagnosis.
What an assessment may involve
- Multimodal retinal imagingA dilated examination, OCT and often autofluorescence or angiographic imaging help establish the characteristic pattern and exclude mimics. OCT angiography can examine abnormal vessels without injected dye, while fluorescein may answer other leakage questions. [1] [5]
- Function beyond chart acuityExplain reading speed, missing letters and difficulties recognizing detail. Selected clinics use microperimetry or other tests of local retinal sensitivity, which can reveal limitations that a central acuity measurement misses. [5] [7]
- Review the actual subtype and complicationAsk whether the diagnosis is type 2 and whether abnormal new vessels are present. A follow-up plan may track photoreceptor changes, symptoms and complication risk; no scan by itself establishes a personal timetable of future loss. [5] [6]
What may help—and what is still being studied
Current implant discussion
ENCELTO delivers ciliary neurotrophic factor from encapsulated modified cells. Trials showed slower loss of a structural photoreceptor marker; reading and sensitivity effects were inconsistent between the two pivotal trials. Discuss likely goals, surgical harms, follow-up and local approval or funding rather than expecting restored normal vision. [3] [4] [7]
Treating neovascular complications
Anti-VEGF injections may help when abnormal new vessels develop. Evidence for routine injections in non-neovascular MacTel is different and uncertain; reducing vessel leakage does not establish prevention of the underlying degeneration. [2] [8]
Monitoring and rehabilitation remain useful
Care includes follow-up and adaptations for central tasks, whether or not a disease-directed treatment is used. Do not start high-dose nutrients on the assumption that metabolic research proves a supplement works; emerging studies require a specialist discussion and verification of eligibility and current results. [2] [5] [9]
What this can mean for daily life
Choose reading formats you can control
Try reflowed text, larger spacing, a line guide and text-to-speech. A practical reading assessment can help identify why reading is slow when a chart score appears reassuring. [5] [9]
Use predictable contrast and lighting
Adjust task lighting and screen contrast to suit your own central-detail needs, with breaks for demanding tasks. These changes improve access and comfort rather than treating the retinal process. [9]
Keep a change-and-appointment record
Note a new task difficulty and which eye seems different, and keep the clinic’s return instructions accessible. Do not wait for an annual appointment when a sudden change occurs. [2]
Connect without substituting peer prescribing
Macular charities offer emotional and practical support, while the MacTel Project provides research information. Registry participation or a peer group is voluntary and separate from clinical care; review consent before sending personal or genetic information. [9] [10]
Bring a clearer description to your appointment
Choose the questions you want to discuss. These choices stay in this page’s memory.
Research, with the context left in
Selected studies and guidance, with their populations and limitations. These are curated educational summaries, not a complete systematic review or a formal evidence rating.
NTMT-03-A and NTMT-03-B: cell-based CNTF therapy
Both found a slower increase in ellipsoid-zone loss with the implant. Reading speed and retinal sensitivity results were inconsistent across trials, and questionnaire and acuity-loss outcomes did not differ significantly. [7]
Limits and applicability: The primary outcome was anatomy, not restored sight; two-year efficacy does not establish lifelong benefit or eliminate procedure-related harms. The sponsor funded the studies.
MacTel Project report 8: visual acuity and advanced disease
Severe acuity loss was uncommon in this registry and related mainly to photoreceptor atrophy; eyes could differ substantially. [6]
Limits and applicability: A cross-sectional distribution is not an individual lifetime risk or a guarantee of preserved reading. Registry selection and chart-based outcomes limit generalization.
Comprehensive MacTel type 2 meta-analysis
Reported diverse phenotypes and supported a distinction between treating proliferative new-vessel disease and uncertain anti-VEGF effects in non-proliferative disease. [8]
Limits and applicability: Mostly heterogeneous observational evidence, with potential overlapping cohorts and confounding. Its search predates the pivotal published 2025 implant trials and is not a complete current regulatory review.
Questions researchers still need to answer
- How well does slowing ellipsoid-zone loss translate into long-term reading and participation benefits?
- Which baseline features predict benefit and harms from an implant or emerging metabolic treatment?
Trusted places to go next
Selected clinical references, research, practical support and ways to connect. Official pages checked 24 October 2026; each entry explains its scope and region.
Macular Society — MacTel
Condition explanation and practical, counseling and peer-support routes. Check current treatment information against the regulator and specialist.
Connections listed by the organization.
Lowy Medical Research Institute — MacTel clinical research
MacTel Project registry and research-participation pathways. Some general web treatment text is older than the 2025 FDA approval; ask about current study status.
US FDA — ENCELTO information
Official indication, approval documents and prescribing information, distinct from a guarantee of coverage or suitability.
Macular Disease Foundation Australia
Macular-disease support navigation and practical central-vision information; individual service eligibility varies.
Connections listed by the organization.
Questions you may still have
Is there really an approved treatment now?
Yes. The FDA approved ENCELTO in March 2025 for adults with idiopathic type 2 MacTel. It is not an approval for all MacTel types, a cure for existing damage or proof of access in every country. [3] [4]
Why is reading difficult when my chart result is good?
Small areas of reduced retinal sensitivity near the center can interrupt whole words without greatly changing the smallest isolated letter you can read. Tell the clinic about real tasks. [5] [7]
Are injections always appropriate?
No. Anti-VEGF treatment is mainly relevant to a secondary neovascular complication; evidence does not establish the same benefit for routine treatment of all non-neovascular cases. [2] [8]
Can a scan cavity simply be treated as edema?
No. MacTel cavities can reflect degenerative tissue changes rather than ordinary fluid-related swelling. Clinical interpretation is needed before choosing treatment. [5]
Sources, image credits and review status
Compiled by VisualSim from clinical references and published research. Sources checked 24 October 2026. Independent clinical review has not been recorded; no named clinical reviewer or clinical validation is claimed. Research evidence and its limitations are linked below.
- ASRS — Idiopathic Juxtafoveal Telangiectasis (n.d.; institution).
Relevant page content and scope checked; source verification is not independent clinical review.
Checked 2026-10-24 · Public page checked - Lowy Medical Research Institute — MacTel FAQs (n.d.; institution).
Clinical symptom and complication text checked; no-approved-treatment sentence is outdated after March 2025 and not adopted.
Checked 2026-10-24 · Public page checked - US FDA — ENCELTO approval and product documents (2025; institution).
Relevant page content and scope checked; source verification is not independent clinical review.
Checked 2026-10-24 · Public page checked - ENCELTO prescribing and patient information, DailyMed (2026; institution).
Current listing effective August 26, 2026; prescribing revision March 2025. Indication, warnings and functional versus anatomical outcomes checked.
Checked 2026-10-24 · Public page checked - Macular Telangiectasia Type 2: The Role of Optical Coherence Tomography and Management Options (2026; review).
Relevant page content and scope checked; source verification is not independent clinical review.
Checked 2026-10-24 · Abstract/indexed material checked; complete full-text review not claimed - Heeren et al. — MacTel Project Report Number 8 (2020; observational).
Relevant page content and scope checked; source verification is not independent clinical review.
Checked 2026-10-24 · Abstract/indexed material checked; complete full-text review not claimed - Chew et al. — Cell-Based Ciliary Neurotrophic Factor Therapy for Macular Telangiectasia Type 2 (2025; trial).
Relevant page content and scope checked; source verification is not independent clinical review.
Checked 2026-10-24 · Abstract/indexed material checked; complete full-text review not claimed - He et al. — Clinical characteristics, imaging features, and treatment outcomes of MacTel type 2: comprehensive meta-analysis (2026; systematic review).
Relevant page content and scope checked; source verification is not independent clinical review.
Checked 2026-10-24 · Full text checked - Macular Society — Macular telangiectasia and support pathways (n.d.; institution).
Relevant page content and scope checked; source verification is not independent clinical review.
Checked 2026-10-24 · Public page checked - Lowy Medical Research Institute — Clinical research (n.d.; institution).
Relevant page content and scope checked; source verification is not independent clinical review.
Checked 2026-10-24 · Public page checked - NHS — Vision loss (n.d.; institution).
Official acute warning-sign guidance read; sudden inability to see or sudden severe eye pain needs emergency care. Local service routes vary.
Checked 2026-10-24 · Public page checked
The simulator helps people communicate an experience. It cannot diagnose a condition, measure a visual field, or establish that someone is safe to drive.